Transcode Therapeutics, Inc. (NASDAQ:RNAZ) 周一宣布，该公司已为其A系列和B系列优先股提交了修订和重述的指定证书。此修订已获得公司A系列无投票权可转换优先股和B系列无投票权优先股大多数持有人的批准，同时也获得了公司董事会的批准。

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Copy the downloaded zip archive to your Synology NAS. Go to Control Panel > Task Scheduler. Select User-defined script. Enter ...

根据研究数据,44%的患者 (16名中的7名)根据RECIST标准显示出持续四个月或更长时间的疾病稳定。公司报告在所有给药剂量范围水平上都有积极的药效学效果,称这与临床前模型和早期0期临床试验结果一致。该股票最近表现出强劲势头,过去一周上涨超过10%,尽管 InvestingPro 分析显示价格波动性显著。

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and ...

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it ...

Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode's outstanding common shares ...

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences. The company also ...